Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.69 |
| ▸ | MME | P08473 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.31 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94502 | 0.91 | AR (0.76) | ARMMEMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL440793 | 0.88 | AR (0.72) | ARMMEMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL95396 | 0.82 | AR (1.00) | ARMME | |
| SCHEMBL438874 | 0.82 | AR (0.64) | ARMMEMAPTSMN1; SMN2 | |
| SCHEMBL96572 | 0.82 | AR (0.64) | ARMMEALDH1A1ALDH3A1ALDH1A3 | |
| SCHEMBL95327 | 0.81 | AR (0.63) | ARMME | |
| SCHEMBL438973 | 0.81 | AR (0.63) | ARMMEALDH1A1ALDH3A1ALDH1A3 | |
| SCHEMBL94331 | 0.81 | AR (0.63) | ARMMEALDH1A1ALDH3A1ALDH1A3 | |
| SCHEMBL94819 | 0.81 | AR (0.63) | ARMMEMAPTALDH1A1 | |
| SCHEMBL94787 | 0.80 | AR (0.62) | ARMMEALDH1A1ALDH3A1ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065231-A1 | THIOPHENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY LTD. (JP) | 2012-03-15 | — | — | US | claimed |
| EP-2426117-A1 | THIOPHENE DERIVATIVE | Sumitomo Chemical Company, Limited (JP) | 2012-03-07 | — | — | EP | claimed |
| US-20120065231-A1 | THIOPHENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065231-A1 | THIOPHENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| EP-2426117-A1 | THIOPHENE DERIVATIVE | Sumitomo Chemical Company, Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065231-A1 | THIOPHENE DERIVATIVE | AR, NR5A1, SHBG | AR 1/4885MME 1367/4885MAPT 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.